ADAG
Adagene Inc.
NASDAQ · Healthcare · Biotechnology · CN
$3.58
−2.98%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 9.4M | 7.7M | 103.2K | 18.1M | 9.3M |
| Cost of Revenue | 1.8M | — | — | — | — |
| Gross Profit | 7.7M | 7.7M | (823.0K) | 18.1M | 9.3M |
| Operating Expenses | |||||
| R&D Expense | 55.7M | 22.0M | 28.8M | 36.6M | 81.3M |
| SG&A Expense | 15.0M | 7.1M | 7.3M | 8.7M | 11.9M |
| General & Admin Expense | 7.4M | 7.1M | 7.3M | 8.7M | 11.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.00 | — | — | (3.5M) | — |
| Total Operating Expenses | 73.5M | 29.1M | 36.1M | 41.8M | 93.2M |
| Cost and Expenses | 74.3M | 29.1M | 36.1M | 41.8M | 93.2M |
| Operating Income (EBIT) | (64.9M) | (21.4M) | (36.0M) | (23.7M) | (83.9M) |
| Non-Operating | |||||
| Interest Income | 5.5M | 2.3M | 3.8M | 4.3M | 377.5K |
| Interest Expense | 1.0M | 463.1K | 851.9K | 1.1M | 693.3K |
| Net Interest Income | 4.5M | 1.8M | 2.9M | 3.2M | (315.8K) |
| Other Non-Op Income/Expense | 5.5M | 3.5M | 2.5M | 6.5M | 4.4M |
| Non-Operating Income (excl Interest) | (3.4M) | (4.0M) | (3.4M) | (7.6M) | (5.1M) |
| EBT (Pre-Tax Income) | (59.4M) | (17.9M) | (33.4M) | (17.3M) | (79.5M) |
| Income Tax Expense | (385.1K) | (297.9K) | (17.6K) | 1.7M | 459.1K |
| Bottom Line | |||||
| Net Income | (59.0M) | (17.6M) | (33.4M) | (18.9M) | (80.0M) |
| Earnings from Cont. Ops | (59.0M) | (17.6M) | (33.4M) | (18.9M) | (80.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (59.0M) | (17.6M) | (33.4M) | (18.9M) | (80.0M) |
| Per Share | |||||
| Basic EPS | ($1.54) | ($0.46) | ($0.95) | ($0.55) | ($2.31) |
| Diluted EPS | ($1.54) | ($0.46) | ($0.95) | ($0.54) | ($2.31) |
| Revenue Per Share | $0.21 | $0.20 | $0.00 | $0.52 | $0.27 |
| Shares | |||||
| Basic Shares Outstanding | 45.3M | 37.8M | 36.0M | 34.6M | 34.6M |
| Diluted Shares Outstanding | 45.3M | 37.8M | 36.0M | 35.0M | 34.6M |
| Profitability Metrics | |||||
| EBITDA | (60.0M) | (16.9M) | (31.7M) | (15.0M) | (77.4M) |
| D&A | 1.6M | 589.8K | 926.2K | 1.2M | 1.4M |
| EBIT | (61.5M) | (17.4M) | (32.6M) | (16.1M) | (78.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026